BackgroundPulmonary rehabilitation (PR) is a cornerstone in Chronic Obstructive Pulmonary Disease (COPD) management. However, PR adherence is generally low, and barriers include availability, economic issues, motivation, and inability to attend or perform physical training. Therefore, alternative, evidence-based PR activities are required. Singing may have benefits within quality of life (QoL), respiratory control, and wellbeing in COPD, but impact on PR key outcome, physical exercise capacity, is uncertain.MethodsIn this RCT (NCT03280355), we investigated effectiveness of 10-weeks of PR, including either “Singing for Lung Health” (SLH)-training or standard physical exercise training (PExT). Primary outcome: Change in exercise capacity (6-Minute Walk Test, distance (6 MWD)) from baseline to post-PR. Secondary outcomes: Changes in QoL (St George's Respiratory Questionnaire (SGRQ)), Hospital anxiety and depression score (HADS), lung function, dyspnoea, and adherence.ResultsWe included 270 COPD patients, and 195 completed the study. Demographics across groups were comparable, and both groups improved significantly in 6 MWD and SGRQ. SLH was non-inferior to PExT in 6 MWD (13.1 m±36.3/14.1 m±32.3; p=0.81 [95%CI=−7.28;9.30]) with 21.8% respectively 25.0% (p=0.57) reaching 6 MWD Minimal Important Difference of 30 m. We found no significant between-group differences concerning SGRQ, HADS, lung function, dyspnoea, or adherence.ConclusionsOur study suggests that SLH is non-inferior to PExT in improving 6 MWD during a 10-weeks PR programme. Future studies addressing reproducibility, long-term effects and health-economics are needed.

Background To our knowledge, there is no intervention which includes personalised exercise therapy and self-management support for people with multimorbidity, although these interventions may be as effective as for people with single chronic conditions. Therefore, we developed a novel intervention, including personalised exercise therapy and self-management support for people with multimorbidity. Methods We followed the Medical Research Council framework and conducted one scoping review, five systematic reviews, two registry-based studies, one qualitative interview study and a mixed-methods feasibility study. Following an iterative approach, together with feedback from people with multimorbidity and relevant stakeholders, we developed the MOBILIZE intervention. Results The intervention included 24 (60 minutes) sessions of personalised exercise therapy and 24 (30 minutes) sessions of self-management support twice a week for 12 weeks, delivered in small groups by specifically trained physiotherapists. The intervention targets physiological, psychosocial, behavioural, and contextual factors to improve health-related quality of life and physical function in people living with multimorbidity. Conclusions We developed a personalised exercise therapy and self-management support programme for people with multimorbidity. The intervention will be tested for its safety and effectiveness in a randomised controlled trial.

Rationale Moderate to severe asthma is associated with impaired asthma control and quality of life (QoL) despite access to specialist care and modern pharmacotherapy. Breathing exercises (BrEX) improve QoL in incompletely controlled mild asthma, but impact in moderate to severe asthma is unknown. Objectives To investigate the effectiveness of BrEX as adjuvant treatment on QoL in patients with uncontrolled moderate to severe asthma. Methods Adult patients with incompletely controlled asthma attending respiratory specialist clinics were randomized to usual specialist care (UC) or UC and BrEX (UC + BrEX) with three individual physiotherapist-delivered sessions and home exercises. Primary outcome was asthma-related QoL (Mini-Asthma Quality of Life Questionnaire [Mini-AQLQ]) at 6 months on the basis of intention-to-treat analysis. Secondary outcomes: Mini-AQLQ at 12 months, lung function, 6-minute-walk test, physical activity level, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale, and adverse events. Repeated-measures mixed-effects models were used to analyze data. Poisson regression models were used to analyze adverse event incidence rate ratio. Results A total of 193 participants were allocated to UC + BrEX ( n = 94) or UC ( n = 99). UC + BrEX was superior in the primary outcome (adjusted mean change difference, 0.35; 95% confidence interval [CI], 0.07 to 0.62). Superiority in Mini-AQLQ was sustained at 12 months (0.38; 95% CI, 0.12 to 0.65). A minor improvement in Hospital Anxiety and Depression Scale depression score at 6 months favoring UC + BrEX (−0.90; 95% CI, −1.67 to −0.14) was observed. Asthma-related adverse events occurred similarly in UC + BrEX and UC participants: 14.9% versus 18.1% ( P = 0.38). Conclusions BrEX as add-on to usual care improve asthma-related QoL in incompletely controlled asthma regardless of severity and with no evidence of harm. Clinical trial registered with www.clinicaltrials.gov (NCT 03127059).